Please provide your email address to receive an email when new articles are posted on . The FDA has approved Vyvgart Hytrulo in a once-weekly, 30- to 90-second subcutaneous injection to treat adults ...

Chronic inflammatory demyelinating polyneuropathy (CIDP) affects the peripheral nerves. Tests to diagnose this condition include nerve conduction studies, electromyography, and sometimes an MRI. CIDP ...

Chronic inflammatory demyelinating polyneuropathy (CIDP) is the most common chronic immune-mediated neuropathy. It affects peripheral nerves and roots. CIDP has no biomarkers. It may be monophasic or ...

The SC formulation of efgartigimod alfa plus hyaluronidase-qvfc is currently marketed under the trade name Vyvgart Hytrulo and is approved for the treatment of generalized myasthenia gravis. The Food ...

Even in remission, chronic inflammatory demyelinating polyneuropathy (CIDP) fatigue can be draining. Learn how to use the spoon theory, pacing strategies, and ergonomic tools to manage your "energy ...

Patients who received Vyvgart Hytrulo experienced a longer time to clinical deterioration compared with those who received placebo. The Food and Drug Administration (FDA) has approved Vyvgart ® ...

Living with chronic inflammatory demyelinating polyneuropathy (CIDP) means managing more than physical symptoms. Learn how to handle ‘relapse anxiety’ and differentiate between normal nerve sensations ...

(RTTNews) - argenx SE (ARGX) announced that Japan's Ministry of Health, Labour and Welfare (MHLW) approved VYVDURA for adults with chronic inflammatory demyelinating polyneuropathy. VYVDURA is ...

Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that ...

VYVGART, the first-in-class FcRn blocker, now offers three administration options, including self-injection with a prefilled syringe Self-injection provides gMG and CIDP patients with flexibility for ...

HyQvia is the only up to once monthly (every 2, 3 or 4 weeks) immunoglobulin subcutaneous infusion to treat CIDP in Canada TORONTO, March 27, 2025 /CNW/ - Takeda Canada Inc. (Takeda) is pleased to ...